John E. Harris, MD, PhD
Research Focus - Using Vitiligo Pathogenesis to Develop Novel Insights into Better Approaches for Melanoma Immunotherapy
- Vitiligo is an autoimmune disease of the skin that results in melanocyte destruction
- Vitiligo patients have a 3-fold lower risk of developing melanoma
- Melanoma immunotherapy using checkpoint inhibitors frequently induces vitiligo, which indicates a better response to treatment
- We have acquired a thorough understanding of vitiligo pathogenesis, and we are using these insights to develop targeted melanoma immunotherapies
Representative Publication
Fakuda K, Okamura K, Riding RL, et al. AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma. J Exp Med. 2021;218(9):e20200962.
In the News
Getting Results…
-
Read more
-
Research News
UMass Cancer Center funds five UMass Chan research projects
Read more -
Community News
John Harris appointed chair of dermatology
Read more -
Research News
John Harris receives Presidential Early Career Award for Scientists
Read more -
Research News
Top story: John Harris lab identifies new pathway to reverse vitiligo
Read more -
Research News
John Harris lab identifies new pathway to reverse vitiligo
Read more -
Research News
John Harris sheds light on treatments for vitiligo in WBZ-TV segment
Read more -
Research News
New treatment in the works for disfiguring skin disease, vitiligo
Read more -
Research News
UMass Medical School vitiligo expert discusses common skin condition
Read more -
Newsmakers, Research News
Telegram story raises awareness of vitiligo, an autoimmune disease afflicting 70 million people
Read more